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Introduction
Chronic paroxysmal hemicrania (CPH) is characterized by
attacks of very severe, unilateral pain, fulfilling criteria of
The International Classification of Headache Disorders,
3rd edition, beta version ( ICHD-3 beta) for paroxysmal
hemicrania and occurring without a remission period, or
with remissions lasting <1 month, for at least 1 year.
Aims
OnabotulinumtoxinA is now used for the treatment of
chronic migraine.We wanted to try the treatment of CPH
with OnabotulinumtoxinA, because other treatments have
not been effective.
Patient and methods
We present the case of a patient diagnosed with CPH
that lasts for 32 years. Attacks of headache lasted about
15 years without remission. The patient described her
headaches as attacks of hemicrania lasted from 15 to 25
minutes with a frequency usually 8 times per day. Onabo-
tulinumtoxinA was infiltrated at eight ipsilateral points.
Total dose was 45 units (each intramuscular injection
site was 0.1 mL = 5 U onabotulinumtoxinA). Seven
points were identical as in the treatment of chronic
migraine in the frontal and temporal areas and one point
was in infraorbital area.Method applications of onabotuli-
numtoxinA based on the methodology of application of
onabotulinumtoxinA in patients with chronic migraine.
Results
The CPH showed a dramatic response to onabotulinum-
toxinA infiltration. Effect of treatment was evident as
early as three weeks after the first injection, gradually
improved, it takes seven months from start of treatment
with 3-monthly infiltrations.
Conclusions
The treatment of CPH with OnabotulinumtoxinA signif-
icantly improved the quality of life of the patient.
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